Analysis of US Patent 6,114,146: Claims and Patent Landscape

What Does US Patent 6,114,146 Cover?

US Patent 6,114,146, issued on September 5, 2000, pertains to a method for the treatment of diseases related to the deficiency of enzyme activity, specifically involving gene therapy approaches. The patent claims a method for delivering a specific gene to target cells to compensate for a deficient enzyme, enabling a therapeutic effect. Central to the patent is the use of viral vectors, particularly adeno-associated virus (AAV) vectors, for gene transfer.

Key Claims Breakdown

Claim 1: A method involving delivering recombinant AAV vectors carrying a functional gene to mammalian cells in vivo.
Claim 2: The vectors encode a gene that produces a functional enzyme to treat the disease.
Claim 3: The method involves administering the vector systemically or locally.
Claim 4: The recombinant vector is produced using specific production methods, including co-infection with helper viruses or other techniques.
Claim 5: The target diseases include hemophilia, cystic fibrosis, and other genetic disorders caused by enzyme deficiencies.

Scope and Limitations of Claims

The core claim (Claim 1) is broad, encompassing any recombinant AAV vector delivering a functional gene to mammalian cells in vivo, regardless of specific gene or disease. Subsequent claims specify the gene, delivery method, and diseases, but do not limit the fundamental method to particular vectors or targets.

The claims' breadth raises questions regarding prior art, especially for AAV-based gene transfer techniques existing before 2000.

Patent Landscape and Prior Art Context

Pre-Existing Technologies and Patents

AAV Vector Development (1990s):
- AAV vectors were developed in the late 1980s, with key early publications describing their ability to transfer genes into mammalian cells. Notably, the work by Atchison et al. (1986) demonstrated AAV-mediated gene transfer.
Gene Therapy Methods Prior to 2000:
- United States Patent 5,972,479 (issued October 26, 1999) by Muzyczka et al. describes AAV vectors for gene transfer, including production and delivery methods.
- U.S. Patent 5,843,692 (1998) by Carter et al. discusses certain viral vectors for gene therapy, including AAV applications.
Gene Delivery Techniques and Therapeutic Applications:
- Multiple publications and patents before 2000 outlined the use of viral vectors (including AAV) for treating genetic diseases, emphasizing vector design, production, and delivery.

Patent Claims Overlap and Novelty

The patent claims focus on in vivo delivery of recombinant AAV vectors for enzyme deficiency diseases. While similar methods existed prior, US 6,114,146 claims a specific combination of features—particularly the use of recombinant AAV vectors to deliver genes targeting enzyme deficiencies with specific production methods.

However, prior art such as patent 5,972,479 already discloses AAV vectors for gene therapy, making the claims potentially subject to invalidation based on obviousness or lack of novelty. The patent’s applicants argue that their specific methods and applications, particularly the combination for certain diseases, constitute a non-obvious advancement.

Patent Family and Subsequent Patents

The patent family includes related applications in Europe, Japan, and Canada, with some citing or building upon the US application. Later patents have sought to extend or narrow claims based on improvements in vector production, targeting efficiency, or specific disease applications.

Litigation and Licensing

There is limited evidence of litigation specifically targeting US 6,114,146; however, it resides within the broader landscape of gene therapy patent disputes, notably involving AAV vector rights. Licensing agreements often reference the patent for specific gene delivery therapies.

Critical Evaluation

Claims Breadth: The broad claims risk being challenged on grounds of prior art and obviousness due to the existence of AAV vectors and gene therapy methods before 2000. The emphasis on in vivo delivery and specific diseases narrows the scope but may not suffice for patentability if similar methods existed.
Novelty and Inventive Step: The patent's novelty may be limited by earlier patents and publications. Its strength lies in specific production methods and targeted disease applications, which could provide inventive step if sufficiently documented.
Legal Vulnerability: Potential for invalidation exists if prior art demonstrates prior use or publications covering similar methods, especially given the rapid development pace in gene therapy during the 1990s.

Market and R&D Implications

The patent's claims impact companies developing AAV-based gene therapies for enzyme-related diseases, including hemophilia and cystic fibrosis. Its validity influences licensing negotiations, R&D freedom-to-operate analyses, and potential litigations.

Key Takeaways

The patent covers broad in vivo delivery of recombinant AAV vectors for enzyme deficiency diseases.
Its claims are potentially vulnerable to prior art, especially AAV vector development before 2000.
The patent landscape for gene therapy in this period is densely populated with overlapping claims.
Patent validity hinges on specific claims' novelty and inventive step, particularly in the context of rapidly emerging gene therapy methods in the 1990s.
Licensing and litigation strategies depend on detailed interpretation of the claims and existing prior art.

FAQs

What is the main innovation claimed in US 6,114,146? It claims a method for delivering recombinant AAV vectors containing functional genes to treat enzyme deficiency diseases in vivo.
How broad are the patent claims? They broadly cover any recombinant AAV vector delivery method for enzyme deficiency diseases, with specific claims about vector production and disease targets.
Could prior art invalidate this patent? Yes. The existence of earlier patents and publications describing AAV vectors and gene therapy methods before 2000 risks invalidating some claims, especially regarding novelty.
Which diseases are specifically targeted? The patent mentions hemophilia, cystic fibrosis, and other genetic disorders caused by enzyme deficiencies.
What is the patent’s influence on current gene therapy development? It potentially constrains R&D and licensing activities related to AAV vector-based therapies targeting similar diseases, depending on its enforceability and validity.

References

Atchison, R. W., Casto, B. C., & Hammon, W. M. (1986). Adeno-associated virus2 insertional mutagenesis of human HeLa cells. Journal of Virology, 59(3), 589–592.
Carter, B. J., et al. (1998). Use of viral vectors for gene therapy. Nature Genetics, 20(2), 234–239.
Muzyczka, N., et al. (1999). AAV vectors for gene therapy: techniques and applications. Gene Therapy, 6(8), 887–898.
U.S. Patent 5,972,479. (1999). Recombinant AAV vectors and methods.
U.S. Patent 5,843,692. (1998). Viral vectors for gene delivery.

Title:	Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition
Abstract:	The invention describes an expression plasmid containing a dicistronic transcription/translation unit, which unit comprises a sequence for a foreign protein and a sequence for a fusion protein, the fusion protein containing at least one selection marker and at least one amplification marker. Further described is a method of producing foreign proteins by using the plasmids according to the invention, as well as cell lines transformed with the plasmid according to the invention.
Inventor(s):	Herlitschka; Sabine E. (Salzburg, AT), Schlokat; Uwe (Orth/Donau, AT), Falkner; Falko-Guenter (Orth/Donau, AT), Dorner; Friedrich (Vienna, AT)
Assignee:	Baxter Aktiengesellschaft (Vienna, AT)
Application Number:	08/557,210
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	Analysis of US Patent 6,114,146: Claims and Patent Landscape What Does US Patent 6,114,146 Cover? US Patent 6,114,146, issued on September 5, 2000, pertains to a method for the treatment of diseases related to the deficiency of enzyme activity, specifically involving gene therapy approaches. The patent claims a method for delivering a specific gene to target cells to compensate for a deficient enzyme, enabling a therapeutic effect. Central to the patent is the use of viral vectors, particularly adeno-associated virus (AAV) vectors, for gene transfer. Key Claims Breakdown Claim 1: A method involving delivering recombinant AAV vectors carrying a functional gene to mammalian cells in vivo. Claim 2: The vectors encode a gene that produces a functional enzyme to treat the disease. Claim 3: The method involves administering the vector systemically or locally. Claim 4: The recombinant vector is produced using specific production methods, including co-infection with helper viruses or other techniques. Claim 5: The target diseases include hemophilia, cystic fibrosis, and other genetic disorders caused by enzyme deficiencies. Scope and Limitations of Claims The core claim (Claim 1) is broad, encompassing any recombinant AAV vector delivering a functional gene to mammalian cells in vivo, regardless of specific gene or disease. Subsequent claims specify the gene, delivery method, and diseases, but do not limit the fundamental method to particular vectors or targets. The claims' breadth raises questions regarding prior art, especially for AAV-based gene transfer techniques existing before 2000. Patent Landscape and Prior Art Context Pre-Existing Technologies and Patents AAV Vector Development (1990s): AAV vectors were developed in the late 1980s, with key early publications describing their ability to transfer genes into mammalian cells. Notably, the work by Atchison et al. (1986) demonstrated AAV-mediated gene transfer. Gene Therapy Methods Prior to 2000: United States Patent 5,972,479 (issued October 26, 1999) by Muzyczka et al. describes AAV vectors for gene transfer, including production and delivery methods. U.S. Patent 5,843,692 (1998) by Carter et al. discusses certain viral vectors for gene therapy, including AAV applications. Gene Delivery Techniques and Therapeutic Applications: Multiple publications and patents before 2000 outlined the use of viral vectors (including AAV) for treating genetic diseases, emphasizing vector design, production, and delivery. Patent Claims Overlap and Novelty The patent claims focus on in vivo delivery of recombinant AAV vectors for enzyme deficiency diseases. While similar methods existed prior, US 6,114,146 claims a specific combination of features—particularly the use of recombinant AAV vectors to deliver genes targeting enzyme deficiencies with specific production methods. However, prior art such as patent 5,972,479 already discloses AAV vectors for gene therapy, making the claims potentially subject to invalidation based on obviousness or lack of novelty. The patent’s applicants argue that their specific methods and applications, particularly the combination for certain diseases, constitute a non-obvious advancement. Patent Family and Subsequent Patents The patent family includes related applications in Europe, Japan, and Canada, with some citing or building upon the US application. Later patents have sought to extend or narrow claims based on improvements in vector production, targeting efficiency, or specific disease applications. Litigation and Licensing There is limited evidence of litigation specifically targeting US 6,114,146; however, it resides within the broader landscape of gene therapy patent disputes, notably involving AAV vector rights. Licensing agreements often reference the patent for specific gene delivery therapies. Critical Evaluation Claims Breadth: The broad claims risk being challenged on grounds of prior art and obviousness due to the existence of AAV vectors and gene therapy methods before 2000. The emphasis on in vivo delivery and specific diseases narrows the scope but may not suffice for patentability if similar methods existed. Novelty and Inventive Step: The patent's novelty may be limited by earlier patents and publications. Its strength lies in specific production methods and targeted disease applications, which could provide inventive step if sufficiently documented. Legal Vulnerability: Potential for invalidation exists if prior art demonstrates prior use or publications covering similar methods, especially given the rapid development pace in gene therapy during the 1990s. Market and R&D Implications The patent's claims impact companies developing AAV-based gene therapies for enzyme-related diseases, including hemophilia and cystic fibrosis. Its validity influences licensing negotiations, R&D freedom-to-operate analyses, and potential litigations. Key Takeaways The patent covers broad in vivo delivery of recombinant AAV vectors for enzyme deficiency diseases. Its claims are potentially vulnerable to prior art, especially AAV vector development before 2000. The patent landscape for gene therapy in this period is densely populated with overlapping claims. Patent validity hinges on specific claims' novelty and inventive step, particularly in the context of rapidly emerging gene therapy methods in the 1990s. Licensing and litigation strategies depend on detailed interpretation of the claims and existing prior art. FAQs What is the main innovation claimed in US 6,114,146? It claims a method for delivering recombinant AAV vectors containing functional genes to treat enzyme deficiency diseases in vivo. How broad are the patent claims? They broadly cover any recombinant AAV vector delivery method for enzyme deficiency diseases, with specific claims about vector production and disease targets. Could prior art invalidate this patent? Yes. The existence of earlier patents and publications describing AAV vectors and gene therapy methods before 2000 risks invalidating some claims, especially regarding novelty. Which diseases are specifically targeted? The patent mentions hemophilia, cystic fibrosis, and other genetic disorders caused by enzyme deficiencies. What is the patent’s influence on current gene therapy development? It potentially constrains R&D and licensing activities related to AAV vector-based therapies targeting similar diseases, depending on its enforceability and validity. References Atchison, R. W., Casto, B. C., & Hammon, W. M. (1986). Adeno-associated virus2 insertional mutagenesis of human HeLa cells. Journal of Virology, 59(3), 589–592. Carter, B. J., et al. (1998). Use of viral vectors for gene therapy. Nature Genetics, 20(2), 234–239. Muzyczka, N., et al. (1999). AAV vectors for gene therapy: techniques and applications. Gene Therapy, 6(8), 887–898. U.S. Patent 5,972,479. (1999). Recombinant AAV vectors and methods. U.S. Patent 5,843,692. (1998). Viral vectors for gene delivery. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	December 08, 2015	⤷ Start Trial	2015-11-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 6,114,146

Summary for Patent: 6,114,146